Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1987-04-16
1991-04-09
Moskowitz, Margaret
Drug, bio-affecting and body treating compositions
Lymphokine
530387, 530388, 424 8591, 43524027, 435 7021, 435948, 436548, 935 96, 935100, 935104, 935107, 935110, C12N 512, C07K 1528, A61K 3900, G01N 3353
Patent
active
050064703
ABSTRACT:
This invention provides a monoclonal antibody, produced by the hybridoma cell line designated GXM1, which specifically binds to a human class 1tumor antigen. This invention also provides a human monoclonal antibody, produced by a hybridoma cell line designated HJM1, which specifically binds to each of the ganglioside antigens GD2, GD3, GM3 and GD1b. This invention further provides a human monoclonal antibody, produced by a hybridoma cell line designated FCM1, which specifically binds to the ganglioside antigens GM3 and GD1a. Finally, this invention provides a human monoclonal antibody, produced by a hybridoma cell line designated DSM1, which specifically binds to a human class 2 tumor protein antigen.
REFERENCES:
patent: 4485093 (1984-11-01), Runge
patent: 4507391 (1985-03-01), Pukel et al.
patent: 4562160 (1985-12-01), Real et al.
patent: 4642291 (1987-02-01), Cairncross et al.
patent: 4675287 (1987-06-01), Reisfeld et al.
patent: 4677070 (1987-06-01), Larrick et al.
patent: 4798790 (1988-01-01), Thomson et al.
Cheresh, D. A., "Localization of the Gangliosides GD.sub.2 and GD.sub.3 in Adhesion Plaques and on the Surface of Human Melanoma Cells," Proc. Nat'l. Acad. Sci. 81:5767-5771, Sep. 1984.
Shichijo, S. et al., "Inhibitory Effects of Gangliosides on Immune Reactions of Antibodies to Neutral Glycolipids in Liposomes," Biochim. Biophys. Acta 858:118-24, 1986.
Livingston, P. O. et al., "Serological Response of Melanoma Patients Receiving Melanoma Cell Vaccines. I. Autologous Cultured Melanoma Cells," Int. J. Cancer 30:413-422, 1982.
Kozbor, D. et al., "Human Anti-Tetanus Toxoid Monoclonal Antibody Secreted by EBV-Transformed Human B Cells Fused with Murine Myeloma," Hybridoma 1(3):323-328, 1982.
Kundu, S. K. et al., "Binding of Monoclonal Antibody A2B5 to Gangliosides," Biochem. Biophys. Res. Commun. 116(3):836-842, Nov. 15, 1983.
Hirabayashi, Y. et al., Biochemistry of Melanoma-Associated Ganglioside Antigens, Chem. Abstracts: 105: 22698 (1986).
Hirabayashi, Y. et al., Syngeneic Monoclonal-Antibody against Melanoma Antigen with Interspecies Cross-Reactivity Recognizes Gm.sub.3, a Prominent Ganglioside of Melanoma, J. Bio. Chem. 260: 13328-13333 (1985).
Houghton, A. et al., Detection of Cell Surface and Intracellular Antigens by Human Monoclonal Antibodies, J. Exp. Med. 158: 53-65 (1983).
Steinitz, M. et al., E.B. Virus-Induced B Lymphocyte Cell Lines Producing Specific Antibody, Nature 269: 420-422 (1977).
Fortunato Sheila R.
Furukawa Koichi
Livingston Philip O.
Lloyd Kenneth O.
Oettgen Herbert F.
Hutzell Paula
Moskowitz Margaret
Sloan-Kettering Institute for Cancer Research
White John P.
LandOfFree
Human monoclonal antibodies to cell surface antigens of melanoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human monoclonal antibodies to cell surface antigens of melanoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibodies to cell surface antigens of melanoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2034197